In vivo spectroscopic photoacoustic imaging and laser‐induced nanoparticle vaporization for anti‐HER2 breast cancer

Yanjie Wang,Muhannad N. Fadhel,Eno Hysi,Maurice Pastenak,Krishnan Sathiyamoorthy,Michael C. Kolios

DOI: https://doi.org/10.1002/jbio.202100099

IF: 3.3899

2021-07-16

Journal of Biophotonics

Abstract:<p>This study reports on the development and application of theragnostic agents targeting the HER2 receptors in breast tumors. The agent was constructed by loading silica-coated gold nanorods (GNRs) and a perfluorohexane liquid into PLGA-PEG nanoparticles, followed by surface conjugation with antibody Herceptin. The particle uptake in human breast cancer MDA-MB-231 (HER2-negative) and BT474 (HER2-positive) cell lines was tested. A proof of principle <i>in vivo</i> study was also performed using a xenograft mouse bilateral tumor model (16 mice, 32 tumors). Photoacoustic imaging was performed using a VevoLAZR device at 720/750/850 nm illuminations and 21 MHz central frequency. The relative concentrations of GNRs in the tumor were quantified using a linear spectral unmixing technique. The therapeutic efficacy of these nanoparticles was evaluated through optical droplet vaporization, and cell damage was confirmed using tissue immunofluorescence and histology. Our results demonstrate the potential of PLGA-GNRs as theragnostic agents for anti-HER2 breast cancer therapy.</p><p>This article is protected by copyright. All rights reserved.</p>

optics,biochemical research methods,biophysics

What problem does this paper attempt to address?

The problem that this paper aims to solve is to develop a kind of theragnostic agents for breast tumors with HER2 receptors. These nanoparticles can simultaneously achieve the monitoring and treatment of early - stage breast cancer. Specifically, the research team designed a kind of nanoparticle based on poly(lactic - co - glycolic acid) - polyethylene glycol (PLGA - PEG). These nanoparticles contain gold nanorods (GNRs) and perfluorohexane liquid, and are combined with the antibody Herceptin on the surface to achieve the selective targeting of HER2 - positive breast cancer cells. Through photoacoustic imaging (PA) and laser - induced nanoparticle vaporization (ODV), this study verified the targeting efficiency and treatment effect of these nanoparticles on breast cancer cells in vitro and in vivo experiments.

The key points of the paper include:
1. **Design and preparation of nanoparticles**: PLGA - PEG nanoparticles containing gold nanorods and perfluorohexane were prepared by the double - emulsion solvent evaporation method, and their surfaces were chemically combined with Herceptin antibodies.
2. **In vitro cell experiments**: The uptake of nanoparticles in HER2 - negative (MDA - MB - 231) and HER2 - positive (BT474) breast cancer cell lines was tested, and their treatment effects were evaluated by photoacoustic imaging and optical titration vaporization techniques.
3. **In vivo experiments**: Using a bilateral tumor xenograft mouse model, the distribution of nanoparticles in tumors was detected by multi - wavelength photoacoustic imaging, and their treatment effects were evaluated by laser - induced vaporization.
4. **Application of photoacoustic spectral unmixing technology**: The contributions of gold nanorods and hemoglobin were separated from photoacoustic signals by using linear spectral unmixing technology, so as to more accurately evaluate the distribution of nanoparticles in tumors.

Through these experiments, the research team demonstrated the potential of PLGA - GNR nanoparticles as theragnostic agents for HER2 - positive breast cancer, especially in improving the detection and treatment effects of early - stage breast cancer.